Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents
- PMID: 479265
- DOI: 10.1007/BF00419285
Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents
Abstract
A cyclophosphamide-resistant subline of a Yoshida ascites tumor was developed by giving increasing doses of the drug after transplantation. The effect of several alkylating agents on the cell proliferation of both the sensitive and resistance cell line was compared establishind dose response curves and D50 values. The developed subline revealed a 260 fold resistance to cyclophosphamide. It was completely cross-resistant to hydroperoxycyclophosphamide, whereas for triaziquone, N-oxide-mustard, and N-methyl-mustard only a partial cross resistance existed. These results give further evidence that cyclophosphamide and hydropeoxycyclophosphamide have the same mechanism of action. Regarding the other alkylating agents the results demonstrate differences concerning either the molecular mode of action or protecting effects. A decreased activation or uptake of substance is probably not the base for resistance.
Similar articles
-
Different uptake of two alkylating substances by ascites tumor cells.Arzneimittelforschung. 1978;28(11):2150-2. Arzneimittelforschung. 1978. PMID: 582920
-
A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro.Cancer Chemother Pharmacol. 1986;17(3):223-6. doi: 10.1007/BF00256688. Cancer Chemother Pharmacol. 1986. PMID: 3742706
-
Preclinical studies and clinical correlation of the effect of alkylating dose.Cancer Res. 1988 Nov 15;48(22):6417-23. Cancer Res. 1988. PMID: 3180059
-
[Pharmacodynamic effect of alkylating cytostatics].Dtsch Med J. 1968 Mar 5;19(5):137-41. Dtsch Med J. 1968. PMID: 4887779 Review. German. No abstract available.
-
Alkylating agents.Cancer Chemother Biol Response Modif. 1992;13:31-44. Cancer Chemother Biol Response Modif. 1992. PMID: 1389913 Review. No abstract available.
Cited by
-
A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.Cancer Immunol Immunother. 1991;32(5):273-9. doi: 10.1007/BF01789044. Cancer Immunol Immunother. 1991. PMID: 1998969 Free PMC article.